Global Metabolic Disorders Therapeutics Market 2016-2020

This market research report analyzes the leading players in the global metabolic disorders therapeutics market such as Novo Nordisk, Sanofi, Merck, AstraZeneca, and Eli Lily. This report also presents a detailed segmentation of the market by type of disease (diabetes drugs, obesity drugs, lysosomal storage disease drugs, and hypercholesterolemia drugs) and by geography (the Americas, APAC, and EMEA). 

Global metabolic disorders therapeutics market forecast

Extensive research carried out by the market research analysts at Technavio has shown that the global metabolic disorders therapeutics market will grow steadily and will post a moderate CAGR of close to 5% over the forecast period. The introduction of patient assistance programs for the treatment of various metabolic disorders is one of the primary factors driving this market’s growth. The leading vendors in the market are providing co-pay assistance to individuals who are purchasing the indicated medications for diabetes, hypercholesterolemia, obesity, and lysosomal storage diseases. Besides this, many organizations such as the National Gaucher Foundation of Canada, National Gaucher Foundation, and the National Organization for Rare Disorders are also involved in providing financial support to patients to continue with the therapy for rare diseases. Since such assistance programs are mostly provided by drug suppliers, patients show more inclination toward buying branded therapeutics, contributing to the metabolic disorders therapeutics market size in the coming years.

One of the upcoming trends gaining traction in the market is the increasing focus on oral insulin therapies. Till now, insulin injections were mostly administered through subcutaneous tissues, but this route of application is associated with risk of infection and hypersensitivity reactions, emboli, high cost, and injection site pain. Also, several needle-phobic individuals hesitate to adopt this route of administration. This paved the way for extensive research in the development of oral insulin. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Moreover, oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.

Competitive landscape and key vendors

The global metabolic disorders therapeutics market is quite consolidated and dominated by the leading players such as Novo Nordisk and Sanofi. The increasing focus on R&D activities and investments by the market leaders ensure that product innovation is given priority. The vendors are competing to gain maximum metabolic disorders therapeutics market share.

Key vendors in this market are 

• Novo Nordisk
• Sanofi
• Merck
• AstraZeneca
• Eli Lily

Other prominent vendors in the market include AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDm, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, NGM Biopharmaceuticals, Norgine BV, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix Biotherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, REGENX BioSciences, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Sanwa Kagaku Kenkyusho, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, SUN Pharma, Takeda, Teva, Thera technologies, Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, and Zydus Cadila.

Segmentation by type of disease and analysis of the metabolic disorders therapeutics market

• Diabetes
• Obesity
• Hypercholesterolemia
• Lysosomal storage diseases

According to this industry research report, the diabetes drugs segment was the leading segment and accounted for close to 64% of the revenue market shares. Depending on the cause, diabetes is essential of three types – type 1 diabetes, type 2 diabetes, and gestational diabetes. The increasing diabetic population globally is one of the significant factors propelling this market segment’s growth. According to various research studies, it is reported that at present nearly 415 million people are affected by diabetes globally, and this number is expected to increase to over 640 million by 2040.

Geographical segmentation and analysis of the metabolic disorders therapeutics market

• Americas
• APAC
• EMEA

In terms of geography, the Americas was the highest revenue contributor in the global metabolic disorders therapeutics market and is likely to reach over USD 46 billion by 2020. The US is the largest revenue contributor in the region. The prevalence of diabetes is increasing at an alarming rate in the US, and various research studies have indicated that nearly half of the adult population in the country has diabetes, or they are at an elevated risk of developing diabetes. Moreover, the implementation of healthcare reforms such as the Affordable Care Act (ACA) is rapidly changing the business environment for pharmaceuticals. Healthcare reforms help reduce the cost of pharmaceutical drugs, offer increased access to healthcare, and improve the quality of healthcare. These healthcare reforms are anticipated to have a positive impact on the region’s market over the next four years.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global metabolic disorders therapeutics market?
• What are the key market trends impacting the growth of the global metabolic disorders therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the global metabolic disorders therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global metabolic disorders therapeutics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global metabolic disorders therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Type 2 Diabetes Market 2016-2020
• Global Type 1 Diabetes Drugs Market 2016-2020
• Global Insulin Delivery Systems Market 2016-2020
• Anti-obesity Drugs Market in the US 2015-2019